Skip to content

Study · Randomized controlled trial · n = 25 · 2022

24 results

Evaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things Technology.

Lin K, Zhang W, He F, Shen J

Computational intelligence and neuroscience22 Jun 2022Cited by 9 (Europe PMC)

PMID35785080 (opens in a new tab)PMCIDPMC9242767 (opens in a new tab)DOI10.1155/2022/8149515 (opens in a new tab)PepBankPUB-35785080
Download PDFPubMedAsk about this study
Jump to 24 results

Summary

ObjectiveTo explore the application value of medical intelligent electronic system under the background of Internet of Things in the clinical study of the treatment of overweight/obesity in type 2 diabetes mellitus (T2DM) with empagliflozin combined with liraglutide; 50 overweight and obese adult T2DM patients in our hospital were randomly divided into the combined group and the control group, 25 cases in each group. The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide. Based on the Internet of Things technology, with diabetes management as the core, the functions of information collection, transmission, and storage of T2DM patients are realized. Doctors pass the diabetes management plan to T2DM patients through the platform, supervise the implementation, and finally compare the clinical efficacy of the two groups.ResultsCompared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment. After combined treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), FPG, 2hPG, HbA1c, and HOMA-IR in the combined group were significantly lower than those in the control group (P < 0.05). Hypoglycemia occurred in both groups, with 2 cases in the control group and 4 cases in the combined group.ConclusionThe telemedicine management system based on Internet of Things technology can improve patients' self-management ability and provide a new choice for individualized treatment of overweight/obesity T2DM patients. The combination therapy of empagliflozin and liraglutide can effectively reduce blood sugar, weight, blood pressure, blood lipid, and hypoglycemia and effectively improve insulin resistance and secretion function of islet β cells in T2DM patients.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study24

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, BMI fell significantly from baseline with liraglutide alone (it also fell in the combined group).

    In plain wordsIn overweight adults with type 2 diabetes, body mass index fell with liraglutide alone compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, fasting glucose fell significantly from baseline with liraglutide alone (it also fell in the combined group).

    In plain wordsIn overweight adults with type 2 diabetes, fasting blood sugar fell with liraglutide alone compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting blood glucose change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, postprandial glucose fell significantly from baseline with liraglutide alone (it also fell in the combined group).

    In plain wordsIn overweight adults with type 2 diabetes, blood sugar after meals fell with liraglutide alone compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial blood glucose change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, HbA1c fell significantly from baseline with liraglutide alone (it also fell in the combined group).

    In plain wordsIn overweight adults with type 2 diabetes, HbA1c fell with liraglutide alone compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, the HOMA-beta index fell significantly from baseline with liraglutide alone (it also fell in the combined group).

    In plain wordsIn overweight adults with type 2 diabetes, the HOMA-beta beta-cell index fell with liraglutide alone compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHOMA-beta change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, HOMA-IR fell significantly from baseline with liraglutide alone (it also fell in the combined group).

    In plain wordsIn overweight adults with type 2 diabetes, insulin resistance fell with liraglutide alone compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHOMA-IR change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, total cholesterol fell significantly from baseline with liraglutide alone (it also fell in the combined group).

    In plain wordsIn overweight adults with type 2 diabetes, total cholesterol fell with liraglutide alone compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal cholesterol change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, triglycerides fell significantly from baseline with liraglutide alone (they also fell in the combined group).

    In plain wordsIn overweight adults with type 2 diabetes, triglycerides fell with liraglutide alone compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglyceride change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.
  9. 09HumanRandomized controlled trialSafety outcome

    In overweight or obese adults with type 2 diabetes, 2 cases of hypoglycemia occurred in the liraglutide-alone control group.

    In plain wordsIn overweight adults with type 2 diabetes, 2 people on liraglutide alone had low blood sugar.

    Peptide
    Liraglutide
    Outcome
    Not applicableHypoglycemia, liraglutide alone
    Study

    n = 25

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Hypoglycemia cases
    2 cases
    control group

    Source sentences

    Summary
    Hypoglycemia occurred in both groups, with 2 cases in the control group and 4 cases in the combined group.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

Studies that did not test the peptide alone15

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 10HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, empagliflozin plus liraglutide significantly lowered BMI from baseline.

    In plain wordsIn overweight adults with type 2 diabetes, empagliflozin plus liraglutide lowered body mass index compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 11HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, empagliflozin plus liraglutide significantly lowered fasting glucose from baseline.

    In plain wordsIn overweight adults with type 2 diabetes, empagliflozin plus liraglutide lowered fasting blood sugar compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting blood glucose change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 12HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, empagliflozin plus liraglutide significantly lowered postprandial glucose from baseline.

    In plain wordsIn overweight adults with type 2 diabetes, empagliflozin plus liraglutide lowered blood sugar after meals compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial blood glucose change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 13HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, empagliflozin plus liraglutide significantly lowered HbA1c from baseline.

    In plain wordsIn overweight adults with type 2 diabetes, empagliflozin plus liraglutide lowered HbA1c compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 14HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, empagliflozin plus liraglutide significantly lowered the HOMA-beta index from baseline.

    In plain wordsIn overweight adults with type 2 diabetes, empagliflozin plus liraglutide lowered the HOMA-beta beta-cell index compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHOMA-beta change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 15HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, empagliflozin plus liraglutide significantly lowered HOMA-IR from baseline.

    In plain wordsIn overweight adults with type 2 diabetes, empagliflozin plus liraglutide lowered insulin resistance compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseHOMA-IR change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  7. 16HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, empagliflozin plus liraglutide significantly lowered total cholesterol from baseline.

    In plain wordsIn overweight adults with type 2 diabetes, empagliflozin plus liraglutide lowered total cholesterol compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal cholesterol change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  8. 17HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, empagliflozin plus liraglutide significantly lowered triglycerides from baseline.

    In plain wordsIn overweight adults with type 2 diabetes, empagliflozin plus liraglutide lowered triglycerides compared with before treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglyceride change from baseline
    Study

    n = 25

    Comparator
    Before treatment
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Compared with before treatment, the body mass index (BMI), fasting blood glucose (FPG), postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc), islet beta cell secretion function index (HOMA-β), islet resistance index (HOMA-IR), total cholesterol (TC), and triglyceride (TG) in both groups decreased significantly after treatment.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  9. 18HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, systolic blood pressure was significantly lower with empagliflozin plus liraglutide than with liraglutide alone.

    In plain wordsIn overweight adults with type 2 diabetes, systolic blood pressure was lower with empagliflozin plus liraglutide than with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure, combined vs liraglutide alone
    Study

    n = 25

    Comparator
    Liraglutide alone
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    After combined treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), FPG, 2hPG, HbA1c, and HOMA-IR in the combined group were significantly lower than those in the control group (P < 0.05).
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  10. 19HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, diastolic blood pressure was significantly lower with empagliflozin plus liraglutide than with liraglutide alone.

    In plain wordsIn overweight adults with type 2 diabetes, diastolic blood pressure was lower with empagliflozin plus liraglutide than with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseDiastolic blood pressure, combined vs liraglutide alone
    Study

    n = 25

    Comparator
    Liraglutide alone
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    After combined treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), FPG, 2hPG, HbA1c, and HOMA-IR in the combined group were significantly lower than those in the control group (P < 0.05).
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  11. 20HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, fasting glucose was significantly lower with empagliflozin plus liraglutide than with liraglutide alone.

    In plain wordsIn overweight adults with type 2 diabetes, fasting blood sugar was lower with empagliflozin plus liraglutide than with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting blood glucose, combined vs liraglutide alone
    Study

    n = 25

    Comparator
    Liraglutide alone
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After combined treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), FPG, 2hPG, HbA1c, and HOMA-IR in the combined group were significantly lower than those in the control group (P < 0.05).
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  12. 21HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, postprandial glucose was significantly lower with empagliflozin plus liraglutide than with liraglutide alone.

    In plain wordsIn overweight adults with type 2 diabetes, blood sugar after meals was lower with empagliflozin plus liraglutide than with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial blood glucose, combined vs liraglutide alone
    Study

    n = 25

    Comparator
    Liraglutide alone
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After combined treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), FPG, 2hPG, HbA1c, and HOMA-IR in the combined group were significantly lower than those in the control group (P < 0.05).
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  13. 22HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, HbA1c was significantly lower with empagliflozin plus liraglutide than with liraglutide alone.

    In plain wordsIn overweight adults with type 2 diabetes, HbA1c was lower with empagliflozin plus liraglutide than with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c, combined vs liraglutide alone
    Study

    n = 25

    Comparator
    Liraglutide alone
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After combined treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), FPG, 2hPG, HbA1c, and HOMA-IR in the combined group were significantly lower than those in the control group (P < 0.05).
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  14. 23HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In overweight or obese adults with type 2 diabetes, HOMA-IR was significantly lower with empagliflozin plus liraglutide than with liraglutide alone.

    In plain wordsIn overweight adults with type 2 diabetes, insulin resistance was lower with empagliflozin plus liraglutide than with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseHOMA-IR, combined vs liraglutide alone
    Study

    n = 25

    Comparator
    Liraglutide alone
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After combined treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), FPG, 2hPG, HbA1c, and HOMA-IR in the combined group were significantly lower than those in the control group (P < 0.05).
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  15. 24HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In overweight or obese adults with type 2 diabetes, 4 cases of hypoglycemia occurred in the empagliflozin plus liraglutide group.

    In plain wordsIn overweight adults with type 2 diabetes, 4 people on empagliflozin plus liraglutide had low blood sugar.

    Peptide
    Liraglutide
    Outcome
    Not applicableHypoglycemia, empagliflozin plus liraglutide
    Study

    n = 25

    Outcome group
    Adverse events · Metabolic and weight

    Measurements

    Hypoglycemia cases
    4 cases
    combined group

    Source sentences

    Summary
    Hypoglycemia occurred in both groups, with 2 cases in the control group and 4 cases in the combined group.
    1 context sentence
    Summary · context
    The control group was treated with liraglutide alone, while the combined group was treated with empagliflozin on the basis of liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.